Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice

  • 17 Accesses

  • 4 Citations

Summary

The distribution and excretion of radioactivity from [14C]-fotemustine was examined in mice with melanomas at different stages of development to determine whether the disease state substantially alters the disposition of the drug and its metabolites. Normal BDF1 mice and mice that had been subcutaneously grafted with B16 melanoma either 1, 3, 7, 14 or 21 days previously were used. The animals were killed at either 5 min, or at 3, 24 or 96 h after receiving an intravenous dose of [14C]-fotemustine (20 mg/kg) and were examined either by whole-body autoradiography or by liquid scintillation counting of excreta and tissues of interest. The majority of the [14C]-fotemustine dose was excreted in the urine, with similar amounts being measured in both non-tumourous animals (61.6%±13.1%) and tumourous mice grafted 14 days previously (67.2%±5.7%). Small amounts of radioactivity, again similar in both non-tumourous and tumourous mice, were recovered in the faeces (5.4%±5.6% and 3.6%±1.8%, respectively) and as carbon dioxide (7%±3.5% and 6.4%±1%, respectively), with minimal amounts being expired as chloroethanol (<1%). When mice were examined 5 min after dosing, there was extensive tissue distribution accounting for 75%±10% of the dose. The highest concentrations determined by both whole-body autoradiography and liquid scintillation counting were measured in the excretory organs, with 33 and 28 μgEq/g being found in the liver and kidney, respectively. High levels were also seen in the lung and plasma (19.8 and 19.5 μgEq/g, respectively). Analysis of variance indicated that groups of tissues, such as the excretory organs, blood and plasma or the pigmented tissues, showed distinct but inconsistent patterns. Only tumours at 14 and 21 days of development were suitable for examination, and these showed levels of 12.1 μgEq/g; however, the tumourto-plasma ratio increased from between approx. 0.5 and 0.6 at 5 min to approx. 2 at 96 h after dosing, suggesting retention within the melanoma, whereas the ratio for the femur remained at approx. 1. Whole-body autoradiography showed that the distribution in the tumour was not uniform, but rather was concentrated in the peripheral area (presumably viable cells) as opposed to the central necrotic region. Thus, the high and sustained concentration of radioactivity found in the active cells of the melanoma may provide an explanation for the high efficacy of the drug.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Castronovo FP, Potsaid MS, Kopiwoda SY (1979) Biodistribution of [14C]-lomustine in an animal tumour model. J Pharm Sci 67: 87–89

  2. 2.

    De Vita VT, Denham C, Davidson JD, Oliverio VT (1967) The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals. Clin Pharmacol Ther 8: 566–577

  3. 3.

    Donelli MG, D'Incalci M, Garattini S (1984) Pharmacokinetic studies of anticancer drugs in tumour-bearing animals. Cancer Treat Rep 68: 381–400

  4. 4.

    Geran RI, Greenberg NH, MacDonald MM, Schumacker AM, Abbot BJ (1972) Protocols for screening chemical agents andnatural products against animal tumours and other biological systems (3rd edn). Cancer Chemother Rep 3: 1–100

  5. 5.

    Godenèche D, Madelmont JC, Labarre P, Plagne R, Meyniel G (1987) Disposition of new sulphur-containing 2-(chloroethyl) nitrosoureas in rats. Xenobiotica 17: 59–70

  6. 6.

    Grunow W, Altmann H-J (1982) Toxicokinetics of chloroethanol in the rat after single oral administration. Arch Toxicol 49: 274–284

  7. 7.

    Khayat D, Lokiec F, Bizzari J-P, Weil M, Meeus L, Sellami M, Rousesse J, Banzet P, Jacquillat C (1987) Phase I clinical study of the new amino acid-linked nitrosourea, S10036, administered on a weekly schedule. Cancer Res 47: 6782–6785

  8. 8.

    Oliveiro VT, Vietzke WM, Williams MK, Adamson RB (1970) The absorption, distribution, excretion and biotransformation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in animals. Cancer Res 30: 1330–1337

  9. 9.

    Payne RW, Lane PW, Ainsley AE, Bicknell KE, Digby PGN, Harding SA, Leech PK, Simpson HR, Todd AD, Verrier PJ, White RP, Gower JC, Tunnscliffe Wilson G, Paterson LJ (1987) GENSTAT 5 reference manual. Clarendon Press, Oxford

  10. 10.

    Ullberg S (1954) Technique used in autoradiographic work. Acta Radiol 118: 22–31

Download references

Author information

Correspondence to R. M. J. Ings.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ings, R.M.J., Breen, M., Devereux, K. et al. The comparative disposition of [14C]-fotemustine in non-tumourous and tumourous mice. Cancer Chemother. Pharmacol. 27, 106–110 (1990). https://doi.org/10.1007/BF00689092

Download citation

Keywords

  • Melanoma
  • Carbon Dioxide
  • Liquid Scintillation Counting
  • Intravenous Dose
  • High Efficacy